Skip to main content
. Author manuscript; available in PMC: 2012 Dec 11.
Published in final edited form as: Maturitas. 2011 Oct 5;70(4):315–321. doi: 10.1016/j.maturitas.2011.09.006

Fig. 2.

Fig. 2

Clinical guidelines in the adjuvant treatment of estrogen positive breast cancer in postmenopausal patients (A–C) or pre/postmenopausal patients (D).

A. Five years of Tamoxifen or aromatase inhibitors can be used as first line adjuvant hormonal therapy in pre or perimenopausal or postmenopausal women respectively. B. In postmenopausal women, sequential therapy with aromatase inhibitor after 2–3 years of tamoxifen is comparable alternative to AI monotherapy. C. Additional 5 years with AIs after 5 years of tamoxifen, have shown significant disease free survival. D. Investigation of extension of tamoxifen beyond 5 years is presently ongoing.